Cargando…

Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes

Background: SAR342434 (SAR-Lis) is a biosimilar (follow-on) of insulin lispro (Humalog(®); Ly-Lis). Two randomized, controlled, open-label, parallel-group, phase 3 studies were conducted to compare the efficacy and safety of SAR-Lis and Ly-Lis, both in combination with insulin glargine (Lantus(®))....

Descripción completa

Detalles Bibliográficos
Autores principales:	Home, Philip, Derwahl, Karl-Michael, Ziemen, Monika, Wernicke-Panten, Karin, Pierre, Suzanne, Kirchhein, Yvonne, Garg, Satish K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771536/ https://www.ncbi.nlm.nih.gov/pubmed/29355435 http://dx.doi.org/10.1089/dia.2017.0373

Ejemplares similares

Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump
por: Thrasher, James, et al.
Publicado: (2018)

Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 2 Diabetes, Also Using Insulin Glargine: SORELLA 2 Study
por: Derwahl, Karl-Michael, et al.
Publicado: (2018)

Similar Pharmacokinetics and Pharmacodynamics of Biosimilar SAR342434 Insulin Lispro and Japan‐Approved Humalog Insulin Lispro in Healthy Japanese Subjects
por: Shiramoto, Masanari, et al.
Publicado: (2022)

Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog®) 100 U/mL
por: de la Peña, Amparo, et al.
Publicado: (2015)

Ultra‐Rapid Lispro results in accelerated insulin lispro absorption and faster early insulin action in comparison with Humalog(®) in Japanese patients with type 1 diabetes
por: Shiramoto, Masanari, et al.
Publicado: (2020)

Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs Humalog(®) Consistently Across Study Populations: A Pooled Analysis of Pharmacokinetic and Glucodynamic Data
por: Leohr, Jennifer, et al.
Publicado: (2021)

Use of Insulin Lispro Protamine Suspension in Pregnancy
por: Lapolla, Annunziata, et al.
Publicado: (2015)

Protocol to Assess the Biological Activity of Insulin Glargine, Insulin Lispro, and Insulin Aspart In Vitro
por: Garige, Mamatha, et al.
Publicado: (2023)

Case of subcutaneous insulin resistance syndrome treated with ultra‐rapid insulin lispro
por: Ishii, Takahiro, et al.
Publicado: (2021)

Efficacy of insulin lispro in improving glycemic control in gestational diabetes
por: Deepaklal, M.C., et al.
Publicado: (2014)

Lispro insulin and electrolyte supplementation for treatment of diabetic ketoacidosis in cats
por: Anderson, Jodie D., et al.
Publicado: (2019)

Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog(®) (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover Study
por: Leohr, Jennifer, et al.
Publicado: (2020)

Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog(®) (Lispro) in Younger Adults and Elderly Patients with Type 1 Diabetes Mellitus: A Randomised Controlled Trial
por: Linnebjerg, Helle, et al.
Publicado: (2020)

Comparison of a Multiple Daily Insulin Injection Regimen (Basal Once-Daily Glargine Plus Mealtime Lispro) and Continuous Subcutaneous Insulin Infusion (Lispro) in Type 1 Diabetes: A randomized open parallel multicenter study
por: Bolli, Geremia B., et al.
Publicado: (2009)

Glucose/insulin-glargine/insulin-lispro: Hepatic glycogenosis, hypoglycaemia and acute hepatitis: case report
Publicado: (2021)

Cost and Utilization Comparisons Among Propensity Score-Matched Insulin Lispro and Regular Insulin Users
por: Hall, Jennifer A., et al.
Publicado: (2003)

The DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) Trial: Comparing the durability of lispro mix 75/25 and glargine
por: Buse, John B., et al.
Publicado: (2011)

Comparison of thrice‐daily lispro 50/50 vs thrice‐daily lispro in combination with sulfonylurea as initial insulin therapy for type 2 diabetes
por: Yamashiro, Keiko, et al.
Publicado: (2010)

Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial
por: Tinahones, F J, et al.
Publicado: (2014)

Effects of Insulin Lispro Mix 25 and Insulin Lispro Mix 50 on Postprandial Glucose Excursion in Patients with Type 2 Diabetes: A Prospective, Open-Label, Randomized Clinical Trial
por: Li, Wei, et al.
Publicado: (2018)

A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus
por: Candido, Riccardo, et al.
Publicado: (2018)

Isolation and Characterization of Acetylated Derivative of Recombinant Insulin Lispro Produced in Escherichia coli
por: Szewczak, Joanna, et al.
Publicado: (2015)

What is the value of faster acting prandial insulin? Focus on ultra rapid lispro
por: Heise, Tim, et al.
Publicado: (2022)

Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO‐Pump‐2
por: Warren, Mark, et al.
Publicado: (2021)

Insulin lispro low mixture twice daily vs basal insulin glargine once daily and prandial insulin lispro once daily as insulin intensification strategies in patients with type 2 diabetes: Latin American subpopulation analysis of a randomized trial
por: Rojas, Arturo, et al.
Publicado: (2016)

Postprandial Vascular Effects of VIAject Compared With Insulin Lispro and Regular Human Insulin in Patients With Type 2 Diabetes
por: Forst, Thomas, et al.
Publicado: (2010)

Efficacy and Safety of Intramuscular Insulin Lispro vs. Continuous Intravenous Regular Insulin for the Treatment of Dogs With Diabetic Ketoacidosis
por: Malerba, Eleonora, et al.
Publicado: (2020)

Comparison of Pharmacokinetics and Pharmacodynamics of Inhaled Technosphere Insulin and Subcutaneous Insulin Lispro in the Treatment of Type 1 Diabetes Mellitus
por: Grant, Marshall, et al.
Publicado: (2021)

Insulin lispro low mixture twice daily vs basal insulin glargine once daily and prandial insulin lispro once daily as insulin intensification strategies in patients with type 2 diabetes: A Latin American subpopulation analysis of a randomized trial
por: Barbieri, Douglas Eugenio, et al.
Publicado: (2015)

Continuous glucose monitoring with Humalog Mix 25 versus Humalog Mix 50, twice daily: A comparative pilot study -Results from the Jikei-EValuation of insulin Lispro mixture on pharmacodynamics and glycemic VariancE (J-EVOLVE) study
por: Nishimura, Rimei, et al.
Publicado: (2010)

Efficacy, Safety, and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin
por: Shah, Viral N., et al.
Publicado: (2021)

Exenatide versus Insulin Lispro Added to Basal Insulin in a Subgroup of Korean Patients with Type 2 Diabetes Mellitus
por: Yoon, Kun-Ho, et al.
Publicado: (2017)

Comparison of Costs and Utilization Between Users of Insulin Lispro Versus Users of Regular Insulin in a Managed Care Setting
por: Chen, Kristina, et al.
Publicado: (2005)

Comparison of morning basal + 1 bolus insulin therapy (insulin glulisine + insulin glargine 300 U/mL vs insulin lispro + insulin glargine biosimilar) using continuous glucose monitoring: A randomized crossover study
por: Takeishi, Soichi, et al.
Publicado: (2017)

Impact of diet on the efficacy of insulin lispro mix 25 and insulin lispro mix 50 as starter insulin in East Asian patients with type 2 diabetes: Subgroup analysis of the Comparison Between Low Mixed Insulin and Mid Mixed Insulin as Starter Insulin For Patients with Type 2 Diabetes Mellitus (CLASSIFY Study) randomized trial
por: Chen, Wei, et al.
Publicado: (2016)

Cumulative clinical experience with use of insulin lispro: critical appraisal, role in therapy, and patient considerations
por: Uy, J, et al.
Publicado: (2012)

An estimation of the long-term clinical and economic benefits of insulin lispro in Type 1 diabetes in the UK
por: Pratoomsoot, C, et al.
Publicado: (2009)

Addition of 20-kDa PEG to Insulin Lispro Alters Absorption and Decreases Clearance in Animals
por: Knadler, Mary Pat, et al.
Publicado: (2016)

DURAbility of Basal Versus Lispro Mix 75/25 Insulin Efficacy (DURABLE) Trial 24-Week Results: Safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes
por: Buse, John B., et al.
Publicado: (2009)

Durability of glycemic control with insulin lispro mix 75/25 versus insulin glargine for older patients with type 2 diabetes
por: Jovanovič, Lois, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_o473asr2armtm7ngsae7snvo61